Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …

Summary Background BRAF V600E mutation occurs in 1–2% of lung adenocarcinomas and
acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown …

Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer
(NSCLC) patients. The most common activating mutation present within the BRAF oncogene …

Summary Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …

Approximately half of BRAF-mutated Non-small cell lung cancers (NSCLCs) harbor a non-
V600 BRAF mutation, accounting for∼ 40,000 annual deaths worldwide. Recent studies …

The management of non-small cell lung cancer (NSCLC) has changed significantly with the
discovery of specific drug targets. These drugs have helped transform patient care and …

Molecular characterization of non-small cell lung cancer (NSCLC) marked an historical
turning point for the treatment of lung tumors harboring kinase alterations suitable for …

Abstract On June 22, 2017, the Food and Drug Administration expanded indications for
dabrafenib and trametinib to include treatment of patients with metastatic non‐small cell lung …

8009 Background: Activating BRAF V600E mutations in NSCLC are present in< 2% of
tumors, primarily adenocarcinoma. The BRAF inhibitor dabrafenib has demonstrated clinical …

Introduction BRAF is a confirmed therapeutic target in non–small cell lung cancer (NSCLC),
as the BRAF inhibitor dabrafenib, in combination with the MEK inhibitor trametinib, is …